SONN Sonnet BioTherapeutic
- 1.7700
- -0.0100-0.56%
- 1.7500
- -0.0200-1.13%
Sonnet BioTherapeutic News
Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting
Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting Download as PDF March 19, 2024 7:30am EDT PRINCETON
RNLX, ASLN and SONN Among Pre-market Losers
Traders Anticipate Inflation Report as US Equities Open Lower on Wall Street
US equities were in red territory after Monday's opening bell as traders looked ahead to the consumer inflation report due for release later in the week for clues on the direction of the Federal Reser
Top Premarket Gainers
Kidpik Corp. (PIK) shares soared more than three-fold Monday premarket following a 5.9% gain in the previous session. The L.S. Starrett Company (SCX) shares surged 56% after the company agreed to a ta
Sonnet BioTherapeutics Announces Early Safety Data From the Company's Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study's Initial Pre-Specified Objective
Safety in the Phase 1b part of Sonnet's double-blind, randomized, controlled trial of SON‐080 was reviewed by the study's Data Safety Monitoring Board (DSMB)The adverse event profile and tolerability
Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers
PRINCETON, NJ / ACCESSWIRE / February 29, 2024 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs for cancer, announced today t
Sonnet BioTherapeutics Is Maintained at Buy by Chardan Capital
Sonnet BioTherapeutics Is Maintained at Buy by Chardan Capital
Chardan Cuts PT on Sonnet BioTherapeutics to $30 From $75 to Reflect Higher Projected Future Share Count, Keeps Buy Rating
Chardan Cuts PT on Sonnet BioTherapeutics to $30 From $75 to Reflect Higher Projected Future Share Count, Keeps Buy Rating.
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersCogent Biosciences (NASDAQ:COGT) shares rose 45.6% to $7.95 during Wednesday's pre-market session. The company's market cap stands at $684.6 million. Lineage Cell Therapeutics (AMEX:LCTX) stock
Sonnet BioTherapeutics GAAP EPS of -$0.31
Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update
Successfully raised approximately $4.55 million in gross proceeds through an underwritten public offeringExtensive preclinical data on SON-1210 published in Frontiers in ImmunologyReceived approval and executed agreement
BTIG Reaffirms Their Buy Rating on Sonnet BioTherapeutics Holdings (SONN)
Sonnet BioTherapeutics Holdings (SONN) Gets a Buy From BTIG
Sonnet Biotherapeutics Holdings Inc Files For Mixed Shelf Of Up To $100M
Sonnet Biotherapeutics Holdings Inc Files For Mixed Shelf Of Up To $100M
Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy
Sonnet BioTherapeutics GAAP EPS of -$18.14 Beats by $9.99, Revenue of $0.15M In-line
Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update
PRINCETON, NJ / ACCESSWIRE / December 14, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic dr
Sonnet BioTherapeutics Initiated at Buy by Ladenburg Thalmann
Sonnet BioTherapeutics Initiated at Buy by Ladenburg Thalmann
Ladenburg Thalmann Initiates Coverage On Sonnet BioTherapeutics With Buy Rating, Announces Price Target of $7
Ladenburg Thalmann analyst Ahu Demir initiates coverage on Sonnet BioTherapeutics (NASDAQ:SONN) with a Buy rating and announces Price Target of $7.
Sonnet BioTherapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 11/27/2023 376.19% Ladenburg Thalmann → $7 Initiates Coverage On → Buy 08/23/2023 355.78% EF Hutton → $6.7
Analysis
Price Target
No Data
